Showing 4791-4800 of 6036 results for "".
- US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina, and Floridahttps://modernod.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/The US Eye practice network has recently expanded its practice base to 50 clinics and five surgery centers across the southeastern United States. Financial terms of the deal were not disclosed. US Eye has partnered with Griffey Eye Care located in Chesapeake, Virginia; Al
- RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditionshttps://modernod.com/news/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions/2480298/The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced the launch of
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter
- Novartis Acquires Arctos Medical, Expanding Optogenetics Portfoliohttps://modernod.com/news/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss/2480291/Novartis announced that it has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Financial terms of the deal were not disclosed. “Optogenetics is emergi
- Glaukos Announces Licensing Agreement with Attillaps Holdingshttps://modernod.com/news/glaukos-announces-licensing-agreement-with-attillaps-holdings-inc/2480289/Glaukos announced that it has entered into a licensing agreement with Attillaps Holdings under which Glaukos will gain a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compound
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Voptica Introduces Inverted Meniscus IOL to Improve Peripheral Vision at ESCRShttps://modernod.com/news/voptica-introduces-inverted-meniscus-iol-to-improve-peripheral-vision-at-escrs/2480285/Voptica SL has introduced what it is calling the first and only inverted meniscus intraocular lens (ArtIOLs) to improve peripheral vision, according to a company news release. Introduced at the 2021 ESCRS symposium in Amsterdam, ArtIOLs mimic the optics of the natural cry
- Luneau Technology and Optovue Announce Mergerhttps://modernod.com/news/luneau-technology-and-optovue-announce-merger/2480284/France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue. Terms of the deal were not disclosed. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology
- Sight Sciences Files Lawsuit Against Ivantis for Patent Infringementhttps://modernod.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/Sight Sciences announced that it has filed a lawsuit in the United States District Court in Delaware against Ivantis for infringement of U.S. Patents that describe and claim devices and methods for reducing intraocular pressure in the eye. The patents are Numbers 8,287,48